COVID 19: Impact on HIV Patient

Abstract

Coronavirus disease 2019 (COVID-19) spreads from person to person mainly through the respiratory route after an infected person coughs, sneezes, sings, talks or breathes. A new infection occurs when virus-containing particles exhaled by an infected person, either respiratory droplets or aerosols, get into the mouth, nose, or eyes of other people who are in close contact with the infected person. People with HIV (PWH) are particularly vulnerable during the time of COVID-19. PWH may not be contracting COVID-19 at disproportionate rates, which is hypothesized to be a function of antiretroviral treatment, PWH who are not taking ART or whose disease is not well managed may be at increased risk for contracting COVID-19 due to having a compromised immune system. The Present article focus the status of HIV Patient coexisting with covid-19 and possible Management by available Anti-Retroviral Therapy.

Lipidomic Profiling and Pharmacological Activities of Ficus drupacea Oil: Comparative Study Between Conventional vs. Green Solvent

“…The inhibitory activities were measured spectrophotometrically at 660 nm using a UV‐Visible spectrophotometer (Systronics 118). Diclofenac sodium was used as a standard at various concentrations [38] . The percent inhibition of protein denaturation was estimated by using formula: $$$\vcenter{\openup.5em\halign{$\displaystyle{#}$\cr {\bf \char37 \ I n h i b i t i o n}=100\times \hfill\cr {{{\bf a b s}.$$…”